Blokhin's Russian Cancer Research Center   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Moscow Russian Federation (1951)

Organization Overview

First Clinical Trial
2004
NCT01176552
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Blokhin's Russian Cancer Research Center | NN Blokhin National Medical Research Center of Oncology | N.N. Blokhin Russian Cancer Research Center | N.N.Blokhin Russian Cancer Research Center

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 3)

Anus Diseases (Phase 3)

Anus Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 3)

Digestive System Neoplasms (Phase 3)

Esophageal Neoplasms (Phase 2)

Esophageal Squamous Cell Carcinoma (Phase 2)

Gastrointestinal Neoplasms (Phase 3)

Glioblastoma (Phase 3)

Lung Neoplasms (Phase 3)

Nausea (Phase 2)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 3)

Neoplasms, Second Primary (Phase 3)

Neoplasms, Squamous Cell (Phase 3)

Rectal Neoplasms (Phase 3)

Stomach Neoplasms (Phase 3)

Vomiting (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 14
  • # of Trial APIs: 22